Food for Thought

  • Most Popular
  • Most Shared

Reuters Showcase

Misleading Snack?

Misleading Snack?

Frito-Lay chips not "all natural": lawsuit.  Full Article 

Truth about Calories

Truth about Calories

Calories count, but not where they come from: study.  Full Article 

Fighting Diseases

Fighting Diseases

Big Pharma donates drugs for neglected diseases.  Full Article 

De-stressing Room

De-stressing Room

San Francisco airport unveils yoga room for travelers.  Full Article 

Benefits of Soy

Benefits of Soy

Study clouds evidence on soy and menopause.  Full Article 

Sun Damage

Sun Damage

More kids seek tans as they age, may raise skin cancer risk.  Full Article 

Take a Dip

Take a Dip

Swimming lowers older adults' blood pressure.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage 

U.S. clears Novartis' youth high blood pressure drug

Related Topics

LOS ANGELES | Tue Dec 4, 2007 3:24am IST

LOS ANGELES (Reuters) - Novartis said on Monday that U.S. regulators approved its drug Diovan to treat high blood pressure in children and adolescents aged 6 to 16.

The drug, also known by its generic name valsartan, is an angiotensin receptor blocker.

The company said research suggests that nearly 5 percent of children and adolescents in the United States may have high blood pressure.

The condition, which had once been mainly found in adults, is striking earlier amid a surge in pediatric obesity rates.

Novartis said no relevant differences were identified between the adverse experience profile for pediatric patients aged six to 16 and that previously reported for adult patients.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.